Are you interested to understand the use, applications and approval process of sustainable rFC tests for endotoxin?
Then view this complimentary webinar addressing the benefits advanced rFC assays offer, including consistency of results and increased lab efficiency.
As the number of companies validating rFC continues to grow, the second part of the webinar covers the implementation through one of the leading rFC users. Eli Lilly has received U.S. FDA approval for Emgality™ (galcanezumab-gnlm) using rFC as release test for bacterial endotoxin. The rFC test replaces the Limulus amebocyte lysate (LAL), thereby eliminating the use of a reagent extracted from live animals.
Part I: Endotoxin Testing Using rFC - Technology, Assays and Applications
Presenter:
Karolina Heed
Global Solution Manager Endotoxins
Hyglos - a bioMérieux company
Part II: rFC - The Road Less Traveled: An Implementation update and Shared Learning.
Presenter:
Jay Bolden
Senior Consultant Quality-Biologist
Global Quality Laboratories of Eli Lilly and Company